Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...
T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...
News Medical on MSN
Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...
The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...
Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...
Potent CAR-T expansion from a single, off-the-shelf infusion without chemotherapy ...
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jonathan L.
T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data from researchers at The University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback